Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease

Fabio Efficace, Franco Mandelli, Paola Fazi, Cristina Santoro, Gianluca Gaidano, Francesco Cottone, Alessandra Borchiellini, Monica Carpenedo, Maria Pina Simula, Valeria Di Giacomo, Micaela Bergamaschi, Iolanda Donatella Vincelli, Francesco Rodeghiero, Marco Ruggeri, Laura Scaramucci, Alessandro Rambaldi, Nicola Cascavilla, Fabio Forghieri, Annamaria Petrungaro, Paolo DitonnoGiovanni Caocci, Sonia Cirrincione, Maria Gabriella Mazzucconi

Research output: Contribution to journalArticlepeer-review


The main objective of this study was to compare health-related quality of life (HRQOL) of primary immune thrombocytopenia (pITP) patients with that of general population, overall, and by patient group (i.e., newly diagnosed, persistent, and chronic patients). Fatigue was also investigated as a secondary objective. Overall, 424 adult patients were enrolled in a multicenter observational study and the control group consisted of a representative sample from the general population. Propensity score matching plus further multivariate linear regression adjustment was used to compare HRQOL outcomes between pITP patients and general population. Mean age of patients was 54 years. Of those with HRQOL assessment, 99 patients (23.6%) were newly diagnosed, 53 (12.6%) were persistent, and 268 (63.8%) were chronic pITP patients. Comparison by patient group versus their respective peers in the general population revealed greater impairments in persistent pITP patients. Persistent pITP patients reported clinically meaningful impairments in physical functioning (−15; 95% CI −24.1 to −5.8; P = 0.002), social functioning (−15.3; 95% CI −25.5 to −5.1; P = 0.004), role physical (−28.4; 95% CI −43.1 to −13.7; P < 0.001), role emotional (−23.9; 95% CI −40.1 to −7.7; P = 0.004), and mental health scales (−11.3; 95% CI −21.2 to −1.4; P = 0.026) of the SF-36 questionnaire. Higher fatigue severity was associated with lower physical and mental HRQOL outcomes. Our findings suggest that the burden of the disease and treatment might depend on the disease phase and that persistent pITP patients are the most vulnerable subgroup. Am. J. Hematol. 91:995–1001, 2016.

Original languageEnglish
Pages (from-to)995-1001
Number of pages7
JournalAmerican Journal of Hematology
Issue number10
Publication statusPublished - Oct 1 2016

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease'. Together they form a unique fingerprint.

Cite this